Codexis, Inc. - Common Stock (CDXS)
Frequently Asked Questions About Codexis, Inc. - Common Stock (CDXS)
Does Codexis engage in partnerships or collaborations?
Yes, Codexis actively seeks partnerships and collaborations with companies, academic institutions, and research organizations. These partnerships are essential for advancing its research and product development efforts, often resulting in the co-development of new applications for its enzyme technology, as well as increasing its market reach and technological expertise.
How can I invest in Codexis, Inc.?
To invest in Codexis, Inc., potential investors can purchase shares through a brokerage account that provides access to the stock market. As a publicly traded company, shares of Codexis (CDXS) can be bought and sold on the NASDAQ exchange. Investors should conduct their research, review the company's financial information, and consider consulting a financial advisor before making investment decisions.
How does Codexis contribute to scientific research?
Codexis contributes to scientific research through its extensive investment in research and development focused on enzyme technology. The company collaborates with universities and research institutions, providing expertise and resources that help advance the field of protein engineering and biocatalysis. By sharing insights and technology, Codexis helps foster innovation in the broader scientific community.
Is Codexis publicly traded?
Yes, Codexis, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol CDXS. The company went public in 2010, providing it with access to capital markets to fund its research and development activities. As a publicly traded entity, Codexis is subject to regulatory requirements and financial oversight.
What are Codexis's core values?
Codexis's core values include innovation, integrity, and sustainability. These values guide the company's approach to business, emphasizing the importance of developing cutting-edge technologies while maintaining ethical standards and a commitment to environmental stewardship. The company encourages a culture of excellence, collaboration, and responsibility among its employees.
What are the key products offered by Codexis?
Codexis offers a range of products that include enzyme-based biocatalysts designed for various applications, such as pharmaceuticals and industrial processes. Their flagship products often cater to the synthesis of active pharmaceutical ingredients (APIs) and other compounds that benefit from enzyme-based reactions. Furthermore, the company also develops custom enzyme solutions tailored to specific customer needs.
What does Codexis, Inc. do?
Codexis, Inc. is a biotechnology company specializing in the development of protein engineering and biocatalysis. The company leverages its proprietary technology platform to design and optimize enzymes for various applications, primarily in the pharmaceutical, industrial, and food sectors. By using its advanced enzyme designs, Codexis aims to enhance the efficiency and sustainability of chemical processes.
What indicates the growth potential of Codexis?
The growth potential of Codexis is indicated by its strong pipeline of enzyme products, the increasing demand for sustainable solutions in manufacturing, and its strategic partnerships and collaborations. The expanding biocatalysis market offers significant opportunities for innovation and increased revenue, particularly as industries strive for more environmentally-friendly production methods.
What industries does Codexis serve?
Codexis serves several industries, including pharmaceuticals, food and beverage, and industrial chemicals. The company's biocatalysis solutions are employed to improve the efficiency of chemical reactions, leading to more sustainable and cost-effective production methods across these sectors. Additionally, Codexis works on applications in agriculture and renewable energy.
What is Codexis's approach to sustainability?
Codexis adopts a sustainability-driven approach by focusing on the optimization of enzymatic processes that reduce waste, minimize energy consumption, and lower the environmental impact of chemical manufacturing. By enabling greener processes through biocatalysis, Codexis is aligning its business goals with global sustainability efforts, contributing to a more circular economy.
What is Codexis's mission?
Codexis's mission is to leverage enzyme engineering technology to create innovative solutions that enhance the efficiency and sustainability of chemical processes. By focusing on protein engineering, Codexis aims to make contributions to the fields of health, agriculture, and industry while fostering a greener future through its sustainable practices.
What is Codexis’s financial performance like?
Codexis has shown varied financial performance in recent years, driven by its investments in research and development and its expansion efforts. Generally, the company aims for growth in revenue through new customer contracts, increased sales of its enzyme products, and ongoing development of new applications. It regularly reports its financial results, including revenue, profit margins, and future guidance.
What recent developments has Codexis announced?
Codexis frequently announces developments regarding its technology advancements, partnerships, and collaborations aimed at expanding its product applications. Recent announcements may include new contract wins for custom enzyme solutions, partnerships with pharmaceutical companies for drug development, and updates on research initiatives to optimize enzyme production processes.
What regulatory requirements does Codexis follow?
As a publicly traded company listed on NASDAQ, Codexis is subject to various regulatory requirements overseen by the U.S. Securities and Exchange Commission (SEC). This includes the submission of quarterly and annual reports, disclosures about financial performance, and compliance with corporate governance standards. Adherence to these regulations ensures transparency and protects shareholders' interests.
When was Codexis, Inc. founded?
Codexis, Inc. was founded in 2002. Since its inception, the company has focused on protein engineering to create innovative biocatalysts that can significantly improve the production processes in various industries. Over the years, Codexis has evolved into a leader in biocatalysis, driven by a commitment to sustainable practices and novel solutions.
Where is Codexis, Inc. headquartered?
Codexis, Inc. is headquartered in Redwood City, California. The location places the company in the heart of the Silicon Valley biotechnology sector, allowing it to collaborate with other leading firms and research institutions. This strategic position has contributed significantly to its growth and innovative capacity.
Who are the main competitors of Codexis?
Codexis competes with several companies in the biocatalysis and enzyme production sectors. Key competitors include Novozymes, DuPont, and DSM, among others. These companies also focus on enzyme technology and bioprocessing solutions for a variety of applications, creating a competitive landscape that drives innovation and development in the biotechnology market.
Who is the CEO of Codexis?
As of my last knowledge update, the CEO of Codexis is Andrew L. A. (Andy) Cawley, who has held the position since 2019. Under his leadership, the company has focused on expanding its enzyme manufacturing capabilities and forging partnerships to accelerate the development of its biocatalysis technologies across various industries.
What is the current price of Codexis, Inc. - Common Stock?
The current price of Codexis, Inc. - Common Stock is 2.110
When was Codexis, Inc. - Common Stock last traded?
The last trade of Codexis, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Codexis, Inc. - Common Stock?
The market capitalization of Codexis, Inc. - Common Stock is 136.39M
How many shares of Codexis, Inc. - Common Stock are outstanding?
Codexis, Inc. - Common Stock has 64.64M shares outstanding.